Raedler, L. A. (2016). Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Am Health Drug Benefits.
Chicago Style CitationRaedler, Lisa A. "Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma." Am Health Drug Benefits 2016.
MLA CitationRaedler, Lisa A. "Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma." Am Health Drug Benefits 2016.
Warning: These citations may not always be 100% accurate.